Novavax Inc. (NVAX) Shares Surge on Positive A/H1N1 Vaccine Results
Biotechnology company Novavax Inc. today announced positive results from its two-stage pivotal study evaluating the safety and immunogenicity (immune response) of the company’s 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine. In response to the results, shares of Novavax rose 12 percent to $2.60 in mid-day trading. The results were consistent with preliminary results that demonstrated that the vaccine was well tolerated and immunogenic at all three dose levels tested. The study is being conducted at the Mexican Institute of Social Security (IMSS), the largest medical and research center in Latin America, by Novavax and Avimex Laboratories of Mexico. The…